Meiji will buy $50 million of unregistered Arcturus securities at $20.27 a share, according to the securities purchase agreement. The shares will represent 7.9% of Arcturus’s outstanding stock after the transaction. Arcturus shares are up 27% over the past 12 months.
In section Market Quotes
Arcturus Shares Gain 10% After Meiji’s $50 Million Investment
Arcturus Therapeutics shares climbed 10% to $9.23 in Monday morning trading after the RNA medicine company announced an expanded collaboration with Meiji Seika Pharma that includes a $50 million equity investment priced at an 80% premium to the market price.

The companies also signed an exclusive license agreement covering the application of Arcturus’ ARCT-154 technology in an undisclosed therapeutic area. Separately, a memorandum of understanding sets out principal terms for a potential collaboration and license agreement on pandemic preparedness and response in Japan using Arcturus’ platform.
Comments (0)
No comments yet. Be the first!